Efficacy and safety of trastuzumab in combination with S-1 and cisplatin therapy for Japanese patients with HER2-positive advanced gastric cancer: Retrospective analysis

Akira Okita, Hiroo Imai, Masahiro Takahashi, Hidekazu Takahashi, Sho Umegaki, Yoshifumi Kawamura, Sakura Hiraide, Kota Ouchi, Yuko Sato, Yoshinari Okada, Keigo Komine, Ken Saijo, Shin Takahashi, Masanobu Takahashi, Hidekazu Shirota, Hisatsugu Ohori, Makio Gamoh, Chikashi Ishioka

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

The combinations of oral fluoropyrimidines and cisplatin such as capecitabine and cisplatin (XP) or S-1 and cisplatin (SP) are regarded as a standard therapy against unresectable, recurrent, or advanced gastric cancer (AGC). Especially, SP is the most common regimen against AGC in Japan. For patients with human epidermal growth factor receptor type 2 (HER2)-positive AGC, trastuzumab, a monoclonal antibody targeting HER2 antibody, is additionally used in combination. Although trastuzumab in combination with XP (trastuzumab-XP) have been widely accepted, the efficacy of trastuzumab in combination with SP (trastuzumab-SP) lacks sufficient verification. The aim of the present study is to validate the comparability of trastuzumab-SP to trastuzumab-XP. Patients with HER2-positive AGC were assigned to the trastuzumab-XP or trastuzumab-SP group. We then retrospectively compared the efficacy and safety between both groups. As a first-line chemotherapy, trastuzumab in combination with XP or SP was administered to 58 patients: 28 with trastuzumab-XP and 30 with trastuzumab-SP. In the trastuzumab-XP group, response rate (RR), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS) were 39.3%, 89.3%, 7.9 months, and 20.0 months, respectively. In the trastuzumab-SP group, RR, DCR, mPFS and mOS were 50.0%, 86.7%, 6.9 months, and 16.7 months, respectively. No significant difference in efficacy was observed between both groups. Severe hand-foot syndrome was observed more frequently in the trastuzumab-XP group than in the trastuzumab-SP group (14.3% vs. 0%, p = 0.05). Trastuzumab in combination with SP is a potential first-line therapeutic option for patients with HER2-positive AGC.

Original languageEnglish
Pages (from-to)123-129
Number of pages7
JournalTohoku Journal of Experimental Medicine
Volume245
Issue number2
DOIs
Publication statusPublished - 2018 Jun

Keywords

  • Chemotherapy
  • Gastric cancer
  • HER2
  • S-1
  • Trastuzumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Efficacy and safety of trastuzumab in combination with S-1 and cisplatin therapy for Japanese patients with HER2-positive advanced gastric cancer: Retrospective analysis'. Together they form a unique fingerprint.

Cite this